Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA clears Immunetics' ELISA for Lyme disease:

This article was originally published in Clinica

Executive Summary

Immunetics has gained US FDA 510(k) clearance to market its ELISA kit for Lyme disease. The C6 Borrelia burgdorferi test kit is based on a peptide, termed C6, which has been shown to be a highly accurate marker for the disease, says the Cambridge, Massachusetts firm. Studies have also revealed that the test substantially reduces the false negative and false positive results associated with current screening tests, claims Immunetics. Significantly, it does not yield false positive results on individuals vaccinated with GlaxoSmithKline Biologicals' Lymerix vaccine, the company adds.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT071644

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel